RUNX2 and familial pancreatic carcinoma: Taken together, our present results strongly suggest that depletion of RUNX2 enhances GEM sensitivity of p53-mutated pancreatic cancer cells through the stimulation of TAp73-dependent cell death pathway, and thus RUNX2 might be an attractive molecular target for the treatment of the patients bearing pancreatic cancer regardless of p53 status.